Home > Insider Trading > Filing (0000950170-24-106532)

Filing Details

Accession Number:: 0000950170-24-106532
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-09-13 18:44:19
Reporting Period:: 2024-09-11

Accepted Time:: 2024-09-13 18:44:19
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1826457	Monte Rosa Therapeutics Inc.	GLUE	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1687880	Versant Venture Capital Vi, L.p.	One Sansome Street, Suite 1650 San Francisco CA 94104	No	No	No	No
1765253	Versant Vantage I, L.p.	One Sansome Street, Suite 1650 San Francisco CA 94104	No	No	No	No
1777651	Versant Vantage I Gp, L.p.	One Sansome Street, Suite 1650 San Francisco CA 94104	No	No	No	No
1777652	Versant Ventures Vi Gp-Gp, Llc	One Sansome Street, Suite 1650 San Francisco CA 94104	No	No	No	No
1777653	Versant Vantage I Gp-Gp, Llc	One Sansome Street, Suite 1650 San Francisco CA 94104	No	No	No	No
1777654	Versant Ventures Vi Gp, L.p.	One Sansome Street, Suite 1650 San Francisco CA 94104	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2024-09-11	541,897	$6.00	6,257,218	No	4	S	Direct
Common Stock	Disposition	2024-09-12	16,047	$6.00	6,241,171	No	4	S	Direct
Common Stock	Disposition	2024-09-13	9,269	$6.16	6,231,902	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	2,097,938	Indirect	See Footnote

Footnotes

The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.00 to $6.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Each of Versant VI GP-GP and Versant VI GP may be deemed to share voting, investment and dispositive power over the shares held by Versant VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.00 to $6.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.02 to $6.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. Each of Versant Vantage I GP-GP and Versant Vantage I GP may be deemed to share voting, investment and dispositive power over the shares held by Versant Vantage I and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.